# Phase I-II to Evaluate Efficacy/Safety of Sorafenib+Gemcitabine+Radiotherapy in Locally Advanced Pancreatic Carcinoma

> **NCT00789763** · PHASE1 · COMPLETED · sponsor: **Grupo Espanol Multidisciplinario del Cancer Digestivo** · enrollment: 12 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine
- **RADIATION:** Radiotherapy
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT00789763
- **Lead sponsor:** Grupo Espanol Multidisciplinario del Cancer Digestivo
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2011-01
- **Final completion:** 2012-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2012-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00789763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00789763, "Phase I-II to Evaluate Efficacy/Safety of Sorafenib+Gemcitabine+Radiotherapy in Locally Advanced Pancreatic Carcinoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00789763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*